Aerovate Therapeutics Inc (AVTE)
19.83
-1.73
(-8.02%)
USD |
NASDAQ |
May 10, 16:00
19.87
+0.04
(+0.20%)
After-Hours: 20:00
Aerovate Therapeutics Total Liabilities (Quarterly): 17.96M for Dec. 31, 2023
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 17.96M |
| September 30, 2023 | 15.15M |
| June 30, 2023 | 13.83M |
| March 31, 2023 | 11.30M |
| December 31, 2022 | 8.558M |
| September 30, 2022 | 8.518M |
| June 30, 2022 | 4.631M |
| Date | Value |
|---|---|
| March 31, 2022 | 5.052M |
| December 31, 2021 | 2.945M |
| September 30, 2021 | 4.277M |
| June 30, 2021 | 84.01M |
| March 31, 2021 | 26.06M |
| December 31, 2020 | 18.06M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
2.945M
Minimum
Dec 2021
84.01M
Maximum
Jun 2021
16.95M
Average
11.30M
Median
Mar 2023
Total Liabilities (Quarterly) Benchmarks
| Insmed Inc | 1.624B |
| Annexon Inc | 47.12M |
| CEL-SCI Corp | 16.06M |
| AIM ImmunoTech Inc | 9.147M |
| IGC Pharma Inc | 2.206M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 127.42M |
| Shareholders Equity (Quarterly) | 109.46M |